Transgene SA (TRGNF)
OTCMKTS · Delayed Price · Currency is USD
1.000
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST
Transgene Employees
Transgene had 147 employees as of June 30, 2025. The number of employees increased by 3 or 2.08% since the number was reported on December 31, 2024.
Employees
147
Change
3
Growth
2.08%
Revenue / Employee
$60,517
Profits / Employee
-$293,847
Market Cap
273.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 147 | 3 | 2.08% |
| Dec 31, 2024 | 144 | 3 | 2.13% |
| Dec 31, 2023 | 141 | -5 | -3.42% |
| Dec 31, 2022 | 146 | 3 | 2.10% |
| Dec 31, 2021 | 143 | 4 | 2.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Transgene News
- 3 months ago - Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript - Seeking Alpha
- 5 months ago - Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 3 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 3 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 3 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 3 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire